suscon green soil insecticide
nufarm australia limited - chlorpyrifos - granular formulation - chlorpyrifos organophosphorus active 100.0 g/kg - miticide - grapevine rootling | hardy ornamental nursery stock - see lab | ornamental nursery plant | tasmanian blue gum | direct seed | el - african black beetle | argentinian scarab | black vine weevil | fiddler beetle | opaline cockchafer | pruinose scarab | sciarid fly | shore fly | bradysia spp.
crinone 8%
pharmacy retailing (nz) ltd t/a healthcare logistics - progesterone 8%{relative} equivalent to to 90 mg progesterone/1.125 g dose; ; - vaginal gel - 8% w/w - active: progesterone 8%{relative} equivalent to to 90 mg progesterone/1.125 g dose excipient: carbomer glycerol palm glycerides hydrog. (equiv. to 11.25 mg/1.125 g dose) light liquid paraffin polycarbophil purified water sodium hydroxide sorbic acid
elaprase
pharmacy retailing (nz) ltd t/a healthcare logistics - idursulfase 2 mg/ml; - concentrate for infusion - 2 mg/ml - active: idursulfase 2 mg/ml excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection - elaprase is indicated for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).
metalyse
boehringer ingelheim (nz) limited - tenecteplase 30mg (recombinant) - powder for injection - 30 mg - active: tenecteplase 30mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.
metalyse
boehringer ingelheim (nz) limited - tenecteplase 40mg (recombinant) - powder for injection - 40 mg - active: tenecteplase 40mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.
metalyse
boehringer ingelheim (nz) limited - tenecteplase 50mg (recombinant) - powder for injection - 50 mg - active: tenecteplase 50mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.
soliris
pharmacy retailing (nz) ltd t/a healthcare logistics - eculizumab 300mg; ; ; - solution for infusion - 300mg/30ml - active: eculizumab 300mg excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - soliris® is indicated for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh)to reduce haemolysis.
thiotepa
pharmacy retailing (nz) ltd t/a healthcare logistics - thiotepa 15mg; - powder for injection - 15 mg - active: thiotepa 15mg
perio-chip
dexcel pharma technologies ltd - chlorhexidine digluconate - chip - chlorhexidine digluconate 2.5 mg - chlorhexidine - chlorhexidine - the perio- chip is indicated for reduction and/or elimination of pathogenic periodontal pocket microbiota, delaying and/or arresting recolonization of the subgingival microflora, reduction and/or elimination of inflammatory lesions in the periodontal pockets, and as an adjunct to mechanical treatment in periodontitis.
naglazyme
medison pharma ltd - galsulfase - concentrate for solution for infusion - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).